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RUNNING TITLE 9 
Mpl loss and β-lactamase production 10 
 11 
ABSTRACT 12 
The hyperproduction of chromosomally encoded β-lactamases is a key method of acquired 13 
resistance to ceftazidime, aztreonam, and when seen in backgrounds having reduced envelope 14 
permeability, carbapenems. Here we show that loss of Mpl, a UDP-muramic acid/peptide ligase, 15 
is a common and previously overlooked cause of chromosomally encoded β-lactamase 16 
hyperproduction in clinical isolates of Stenotrophomonas maltophilia and Pseudomonas 17 
aeruginosa, important pathogens notorious for their β-lactam resistant phenotypes. 18 
 19 
TEXT 20 
Stenotrophomonas maltophilia clinical isolates are resistant to almost all β-lactams because of the 21 
production of two β-lactamases: L1, a subclass B3 metallo-β-lactamase and L2, a class A extended 22 
spectrum β-lactamase (1) Production of L1 and L2 is co-ordinately controlled by AmpR, a LysR-type 23 
transcriptional activator and induced during β-lactam challenge of cells (2). Where previously 24 
characterised, AmpR regulators have been shown to bind two ligands in a competitive manner (3, 4). 25 
As summarised in Figure 1, the AmpR activator ligand, an anhydro-muramyl-penta-peptide is produced 26 
during β-lactam challenge via the concerted actions of lytic transglycosylases, which release 27 
N-acetylglucosamine-anhydro-muramyl-peptides from peptidoglycan (5) and AmpG, a permease that 28 
transports them into the cytoplasm (6, 7). NagZ, an enzyme that removes the N-acetylglucosamine 29 
moiety is also necessary to release the AmpR activator ligand in some species (8), though not in 30 
S. maltophilia (9). The AmpR repressor ligand is a UDP-muramyl-penta-peptide (10). It is produced 31 
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via sequential addition of amino acids to a UDP-muramyl substrate, via four separate ligase enzymes, 32 
MurC (11), MurD (12), MurE (13) and MurF (14), with the last adding a D-alanine/D-alanine dipeptide 33 
made by a fifth ligase enzyme, Ddl (15). Mpl is an enzyme that can ligate a ready-made penta-peptide 34 
onto the UDP-muramyl substrate, skipping the MurC, D, E, Ddl and MurF ligation reactions, each of 35 
which requires ATP hydrolysis (16). This Mpl catalysed reaction therefore saves considerable amounts 36 
of energy for the cell. Its penta-peptide substrate comes from breakdown of 37 
anhydro-muramyl-penta-peptides by the peptide amidase AmpD. In this way, breakdown of the 38 
anhydro-muramyl-penta-peptide AmpR activator ligand by AmpD is also directly linked to production 39 
of the UDP-muramyl-penta-peptide AmpR repressor ligand by Mpl (2, 5, 17, 18) (Fig. 1). 40 
Ceftazidime is a relatively weak substrate for both L1 and L2 β-lactamases from S. maltophilia, and so 41 
many clinical isolates remain ceftazidime susceptible (1). However, mutants that have acquired 42 
ceftazidime resistance can easily be identified in the laboratory, and ceftazidime resistant isolates are 43 
commonly encountered in the clinic. In most cases, these mutants hyperproduce L1 and L2 (19). 44 
Mutations that reduce AmpD function are known to boost L1/L2 production, because the AmpR 45 
activator ligand is broken down much less if AmpD is damaged (20). Mutations that (presumably) 46 
increase peptidoglycan turnover, releasing more muropeptides, also activate L1/L2 production, e.g. 47 
those in PBP1A, encoded by mcrA (21) and in the lytic transglycosylase MltD, because this mutation 48 
stimulates the net production of lytic transglycosylase activity in the cell (22). Mutations in AmpR also 49 
activate L1/L2 production (4). We have previously characterised ceftazidime resistant, β-lactamase 50 
hyper-producing laboratory selected mutants derived from the extremely well studied clinical isolate 51 
K279a. One of these mutants, KCAZ14, was wild-type for ampR, ampD, and mcrA (19). To identify 52 
the mutation responsible, whole genome resequencing was performed by MicrobesNG (Birmingham, 53 
UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using 54 
Trimmomatic (23) and assembled into contigs using SPAdes 3.10.1 55 
(http://cab.spbu.ru/software/spades/). Assembled contigs were mapped to reference genome for 56 
S. maltophilia K279a (24) obtained from GenBank (accession number NC_010943) using 57 
progressiveMauve alignment software (25). The only mutation identified in KCAZ14 was a deletion of 58 
18 nucleotides in mpl gene, deleting amino acids 141-146 of Mpl. The level of β-lactamase production, 59 
measured as previously (19) was similar for the mpl mutant KCAZ14, for an ampD loss of function 60 
mutant KCAZ10 (19) and for KM11, an ampR activatory mutant (4) (Table 1). To confirm involvement 61 
of mpl loss in the β-lactamase hyper-producing, ceftazidime resistant phenotype of KCAZ14, we 62 
attempted complementation in trans. K279a mpl was amplified by PCR as previously (19) with primers 63 
mpl_F (5’-ACCAGATCCAGGTACCGCC-3’), mpl_R (5’-TCTCACATCCCGTGTAGGACT-3’). 64 
The product was blunt-end ligated into pBBRMCS-5 (GmR) (26, 27) digested with SmaI and the 65 
resulting recombinant plasmid used to transform KCAZ14 to gentamicin resistance (15 µg.mL-1) via 66 
electroporation. The ceftazidime MIC against KCAZ14(pBBRMCS-5) was 64 µg.mL-1 and reduced to 67 
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4 µg.mL-1 in KCAZ14(pBBRMCS-5::mpl), the same as the MIC against wild-type K279a. Production 68 
of β-lactamase was also reduced to wild-type levels in KCAZ14(pBBRMCS-5::mpl) (Table 1) adding 69 
further confirmation of successful complementation.  70 
We have four ceftazidime resistant, β-lactamase hyperproducing clinical S. maltophilia clinical isolates 71 
in our collection: isolates 49-6147, 3800 and 98 (19) and ULA-511 (28) (Table1). Isolate 98 has an 72 
Insertion Sequence element disrupting ampD (19). Whilst we also found a mutation causing an 73 
Ala85Gly change in Mpl, the same mutation is carried by ~5% of S. maltophilia genomes in the 74 
Genbank database so is probably insignificant. The other three clinical isolates have mpl mutations. In 75 
49-6147, the mutation causes the deletion of amino acids 92-109, which disrupts the conserved 76 
Ser-Gly-Pro region (29). In 3800, there is a frameshift at codon 368 and in ULA-511 there is a nonsense 77 
mutation at codon 360. 78 
The result of Mpl loss in KCAZ14 and these clinical isolates will be a build-up of penta-peptides 79 
released by AmpD (Fig. 1). Even though there are other enzymes that can break down these penta-80 
peptides, it seems reasonable to hypothesise that this net accumulation of penta-peptide will affect 81 
AmpD activity by feedback inhibition, increasing the concentration of its substrate, the AmpR activator 82 
ligand, causing β-lactamase hyper-production (18).  83 
This is the first report of mpl disruption causing β-lactamase hyperproduction in S. maltophilia, and to 84 
find it in 3/4 clinical isolates was striking. It is also interesting to find that mpl loss of function mutations 85 
have been seen to accumulate in Pseudomonas aeruginosa populations carried by people with Cystic 86 
Fibrosis during long term colonisation in two separate studies (30, 31) and also in 3/4 patients with 87 
P. aeruginosa mediated ventilator associated pneumonia (32). Indeed, mpl mutation has been identified 88 
as a cause of AmpC β-lactamase hyperproduction in one P. aeruginosa PAO1 laboratory selected 89 
transposon-insertion mutant (33). Whilst this did not dramatically increase β-lactam MICs (33), PAO1 90 
is relatively permeable to β-lactams, because it lacks many of the efflux pump/porin altering mutations 91 
seen in clinical isolates (34). Therefore, it would seem reasonable to propose that these clinically 92 
acquired P. aeruginosa mpl mutations are being selected by β-lactam therapy. We have a small 93 
collection of ceftazidime resistant P. aeruginosa clinical isolates, of which 2/5 have previously been 94 
confirmed to hyperproduce AmpC (35). Both have a mutation in mpl, according to whole genome 95 
sequencing. The mutations in isolates 86-14571 and 73-56826 cause Met297Val and an Arg103His 96 
changes in Mpl, respectively. We conclude, therefore, that mpl loss in S. maltophilia and P. aeruginosa 97 
is a clinically important and previously under-reported cause of β-lactamase hyperproduction and 98 
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Fig 1 109 
 110 
 111 
Fig 1 Role of Mpl in peptidoglycan recycling and AmpR activation. 112 
The schematic shows that N-acetylglucosamine (black square)-anhydro-muramyl (green diamond)-113 
penta-peptide (purple triangle) is removed from peptidoglycan by lytic transglycosylases such as Slt70 114 
and enters the cytoplasm through the permease AmpG. NagZ removes the N-acetylglucosamine group 115 
to produce the anhydro-muramyl-penta-peptide AmpR activator ligand (“+ve”). AmpD then releases 116 
the penta-peptide ready to be linked to a UDP-muramic acid molecule (red diamond) by Mpl to produce 117 
the UDP-muramyl-penta-peptide AmpR repressor ligand (“-ve”). This can then be further incorporated 118 
into the biosynthetic pathway and processed by MurG and MraY, which add N-acetylglucosamine and 119 
penicillin binding proteins, which add these high energy N-acetylglucosamine-muramyl (white 120 
diamond)-penta-peptide substrates to the nascent peptidoglycan strand. UDP-muramyl-penta-peptide 121 
formation can also occur without peptidoglycan recycling, through the sequential addition of amino 122 
acids to UDP-Muramic acid. However, this requires five moles of ATP per mole of UDP-muramyl-123 





Table 1 127 
β-Lactamase activity (nmol.min-1.µg-1 protein nitrocefin hydrolysed in cell extracts) observed in 
S. maltophilia K279a and in ceftazidime resistant K279a mutants and clinical isolates carrying 
different mutations. 
Isolate Mean β-lactamase 
activity ±SEM 
Relevant amino acid changes 
(Relative to K279a) 
K279a 0.02±0.004 WT 
KM11 0.99±0.03 Asp135Asn in AmpR 
KCAZ10 1.52±0.04 159-168del in AmpD 
KCAZ14 0.72±0.01 140-146del in Mpl 
49-6147 0.45±0.12 92_109del Mpl 
3800 0.73±0.03 Truncation at 368 in Mpl 
98 1.76±0.07 IS insertion in ampD; Ala85Gly* in Mpl 
ULA-511 1.19±0.01 Truncation at 360 in Mpl 
   
KCAZ14 (pBBRMCS-5) 1.14±0.10  
KCAZ14 (pBBRMCS-5::mpl) 0.03±0.003  
 128 
*Random Genetic Drift 129 
WT: Wild type 130 
 131 
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